Kiniksa Pharmaceuticals International, plc (KNSA)
(Delayed Data from NSDQ)
$35.77 USD
-0.79 (-2.16%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $35.74 -0.03 (-0.08%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KNSA 35.77 -0.79(-2.16%)
Will KNSA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KNSA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KNSA
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
KNSA: What are Zacks experts saying now?
Zacks Private Portfolio Services
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
Other News for KNSA
Slingshot Bullish appears for KNSA after 1.46% move
Tracking Baker Brothers Portfolio - Q2 2025 Update
KNSA makes New 52 Week Closing High on September 12
Is KNSA positioned for a breakout? New 52 Week Closing High shows up after rising 2.15%
Is KNSA set to rally? New 52 Week High shows up after sliding 1.71%